140 related articles for article (PubMed ID: 38500445)
1. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X
Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
Illés Á; Pinczés LI; Egyed M
Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
[TBL] [Abstract][Full Text] [Related]
3. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T; Vannucchi AM; De Stefano V; Masciulli A; Carobbio A; Ferrari A; Ghirardi A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
[TBL] [Abstract][Full Text] [Related]
4. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
[TBL] [Abstract][Full Text] [Related]
5. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
[TBL] [Abstract][Full Text] [Related]
7. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
Wagner SM; Melchardt T; Greil R
Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K
Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
[TBL] [Abstract][Full Text] [Related]
9. Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.
Suo SS; Fu RF; Qin A; Shao ZH; Bai J; Chen SN; Duan MH; Zhou H; Xu N; Zhang SJ; Zuo XL; Du X; Wang L; Li P; Zhang XH; Wu DX; Li YN; Zhang JJ; Wang W; Shen WH; Zagrijtschuk O; Sato T; Xiao ZJ; Jin J
J Hematol; 2024 Apr; 13(1-2):12-22. PubMed ID: 38644985
[TBL] [Abstract][Full Text] [Related]
10. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
[TBL] [Abstract][Full Text] [Related]
12. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger H; Zagrijtschuk O; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Kralovics R; Gisslinger B; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Schalling M; Them NC; Kadlecova P; Klade C; Greil R
Blood; 2015 Oct; 126(15):1762-9. PubMed ID: 26261238
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
Gerds AT; Castro C; Snopek F; Flynn MM; Ellis AG; Manning M; Urbanski R
J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
[No Abstract] [Full Text] [Related]
14. Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
Popova-Labachevska M; Cvetanoski M; Ridova N; Trajkova S; Stojanovska-Jakimovska S; Mojsovska T; Stojanoski Z; Pivkova-Veljanovska A; Panovska-Stavridis I
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Dec; 44(3):57-62. PubMed ID: 38109450
[No Abstract] [Full Text] [Related]
15. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
Huang YW; Qin A; Fang J; Wang TF; Tsai CW; Lin KC; Teng CL; Larouche R
Br J Clin Pharmacol; 2022 May; 88(5):2396-2407. PubMed ID: 34907578
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.
Qin A
Clin Ther; 2024 May; 46(5):439-440. PubMed ID: 38697872
[No Abstract] [Full Text] [Related]
17. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
Jin J; Zhang L; Qin A; Wu D; Shao Z; Bai J; Chen S; Duan M; Zhou H; Xu N; Zhang S; Zuo X; Du X; Wang L; Li P; Zhang X; Li Y; Zhang J; Wang W; Shen W; Zagrijtschuk O; Urbanski R; Sato T; Xiao Z
Exp Hematol Oncol; 2023 Jun; 12(1):55. PubMed ID: 37344895
[TBL] [Abstract][Full Text] [Related]
18. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
Hsu SJ; Yu ML; Su CW; Peng CY; Chien RN; Lin HH; Lo GH; Su WW; Kuo HT; Hsu CW; Yang SS; Yang SS; Tseng KC; Qin A; Huang YW; Chuang WL
J Formos Med Assoc; 2021 Mar; 120(3):956-964. PubMed ID: 33077341
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
[TBL] [Abstract][Full Text] [Related]
20. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]